Home > Oncology > ESMO 2019 > CNS Tumours > Adding bevacizumab to temozolomide-based therapy in neuroblastoma

Adding bevacizumab to temozolomide-based therapy in neuroblastoma

ESMO 2019
Phase 2, BEACON-Neuroblastoma

The addition of bevacizumab to temozolomide-based therapy was associated with an improvement in overall response (OR) in children with relapsed/refractory neuroblastoma enrolled in the phase 2 BEACON-Neuroblastoma clinical trial.

Patients with relapsed or refractory neuroblastoma aged 1- 21 years were randomly assigned to receive treatment in 5 experimental arms: temozolomide-bevacizumab; irinotecan-temozolomide; irinotecan-temozolomide-bevacizumab; temozolomide-topotecan; and topotecan-temozolomide.

The primary end point for part 1 (n=106) of the study was best response, with at least 4 more responses in the bevacizumab plus chemotherapy arms compared with the chemotherapy alone arms set as the criterion for a positive result. In total, 17 of 52 patients (33%) receiving chemotherapy plus bevacizumab and 8 of 54 patients (15%) receiving chemotherapy alone had an objective response to trea...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on